UCB (STU:UNC) Other Operating Expense: €-925 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
91 GF Score
Price €224.00
GF Value €249.08
Valuation Modestly Undervalued
View Full Analysis

What is UCB Other Operating Expense?

UCB STU:UNC +1.73% 91 Other Operating Expense is €-925 Mil as of Jun. 2026. GuruFocus rates STU:UNC with a GF Score™ of 91/100 and a GF Value™ of €249.08 (Modestly Undervalued).

UCB's Other Operating Expense for the six months ended in Jun. 2026 was €-394 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-925 Mil.

UCB's quarterly Other Operating Expense declined from Jun. 2025 (€-293 Mil) to Dec. 2025 (€-531 Mil) but then increased from Dec. 2025 (€-531 Mil) to Jun. 2026 (€-394 Mil).

UCB's annual Other Operating Expense declined from Dec. 2023 (€-542 Mil) to Dec. 2024 (€-574 Mil) and declined from Dec. 2024 (€-574 Mil) to Dec. 2025 (€-824 Mil).

UCB Other Operating Expense Historical Data

* Premium members only.

The historical data trend for UCB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Other Operating Expense Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -166.00 -243.00 -542.00 -574.00 -824.00

UCB Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -249.00 -325.00 -293.00 -531.00 -394.00
STU:UNC
91GF Score
UCB SA STU:UNC
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-925 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €-925 Mil mean?
UCB (STU:UNC) has a Other Operating Expense of €-925 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on UCB and its competitors.
Is UCB's Other Operating Expense too high?
UCB's current Other Operating Expense is €-925 Mil. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Other Operating Expense compare to VRTX and REGN?
UCB's Other Operating Expense of €-925 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on UCB and its competitors. UCB's current Other Operating Expense is €-925 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €249.08, compared to a current price of €224.00 — trading 10.1% below its estimated fair value. The current Other Operating Expense is €-925 Mil. UCB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For UCB (STU:UNC), the current Other Operating Expense is €-925 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of €224.00 is trading 10.1% below its estimated GF Value™ of €249.08. GuruFocus considers UCB to be Modestly Undervalued.

Key valuation signals for STU:UNC:

  • Other Operating Expense: €-925 Mil
  • GF Value™: €249.08 vs. price of €224.00 (10.1% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score

Get the complete analysis for STU:UNC

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€224.00
Price
€249.08
GF Value